La catena delle opzioni mostra i dati chiave delle opzioni azionarie di Allogene Therapeutics a vari prezzi di esercizio e date di scadenza. I trader utilizzano queste informazioni per analizzare potenziali operazioni e valutare il sentiment del mercato per Allogene Therapeutics..

Allogene Therapeutics (NASDAQ:ALLO) Azioni, Catena delle Opzioni

ALLOGENE THERAPEUTICS INC

Allogene Therapeutics

Allogene Therapeutics Inc is a clinical-stage biotech firm specializing in immuno-oncology, focusing on the development of genetically engineered allogeneic T-cell products for cancer and autoimmune diseases. Their pipeline includes off-the-shelf T-cell candidates designed to target cancer cells or autoreactive cells in autoimmune disorders. Notably, their allogeneic approach, derived from healthy donors, allows for broader patient eligibility and scalability. With a vision to redefine CAR T therapy, the company concentrates on core programs targeting lymphoma, leukemia, autoimmune diseases, and solid tumors. Revenue, generated from collaborations and licensing agreements, supports their research and development efforts.

Allogene Therapeutics, Inc. - Common Stock

Allogene Therapeutics Inc

Allot Ltd

ALLON THERAPEUTICS INC by Allon Therapeutics Inc.

ALLOVIR INC

News

Press Releases

Allogene Therapeutics to Report First Quarter 2025 Financial Results and Provide Business Update

Earnings

Allogene Therapeutics Reports First Quarter 2025 Financial Results and Business Update

Health Care

Allogene Therapeutics Announces ASCO 2025 Abstract Publication Featuring Oral Presentation of ALLO-316 in Kidney Cancer and ALPHA3 TIP Poster for Cema-Cel

Allogene Therapeutics Announces Participation in Upcoming Investor Conferences

Allogene Therapeutics Provides Updated Phase 1 Data Highlighting Durable Responses with ALLO-316 in Heavily Pretreated Advanced Renal Cell Carcinoma at ASCO

Small Cap

Opinion

High‑Growth Oncology Market Projected For US$900bn in Revenue Despite Policy Headwinds

Allogene Therapeutics Moves Forward with Standard Fludarabine and Cyclophosphamide (FC) Lymphodepletion Regimen in the ALPHA3 Trial for Cemacabtagene Ansegedleucel (Cema-Cel) in First-Line Consolidation for Large B-Cell Lymphoma

Allogene Therapeutics to Report Second Quarter 2025 Financial Results and Provide Business Update

Allogene Therapeutics Reports Second Quarter 2025 Financial Results and Business Update

Allogene Therapeutics Announces Participation in Upcoming Investor Conference

ALLO

CATX

ONCY

TSX:ONC

VSTM

Abeona Therapeutics

AC Immune

Aldeyra Therapeutics, Inc. - Common Stock

Aldeyra Therapeutics

Alector

Candel Therapeutics

Cullinan Therapeutics, Inc. - Common Stock

Cullinan Therapeutics

DBV Technologies S.A. - American Depositary Shares

DBV Technologies

Enanta Pharmaceuticals, Inc. - Common Stock

Enanta Pharma

Eupraxia Pharmaceuticals Inc. - Common Stock

Eupraxia Pharmaceuticals

Fennec Pharmaceuticals Inc. - Common Stock

Fennec Pharmaceuticals

Galectin Therapeutics Inc. - Common Stock

Galectin Therapeutics

Humacyte

Immutep Limited - American Depositary Shares

Immutep

Ironwood Pharmaceuticals, Inc. - Class A Common Stock

Ironwood Pharmaceuticals

Jade Biosciences

Kyverna Therapeutics, Inc. - Common Stock

Kyverna Therapeutics

Lyell Immunopharma

Mereo BioPharma Group plc - American Depositary Shares

Mereo BioPharma Group

Neurogene

Puma Biotechnology

Cartesian Therapeutics, Inc. - Common Stock

Cartesian Therapeutics

Tectonic Therapeutic, Inc. - Common Stock

Tectonic Therapeutic

Vanda Pharmaceuticals Inc. - Common Stock

Vanda Pharmaceuticals

Voyager Therapeutics, Inc. - Common Stock

Voyager Therapeutics

Zura Bio Limited - Class A Ordinary shares

Comments

Allogene Therapeutics

Allogene Therapeutics (ALLO) Opzioni

Allogene Therapeutics (NASDAQ:ALLO) Azioni, Catena delle Opzioni

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO